TB-500 Fragment 17-23 vs TB-500: What's the Difference?

TB-500 fragment 17-23 is the short, seven-amino-acid active region of thymosin beta-4, while TB-500 is the label most vendors use for a synthetic version of the full 43-amino-acid thymosin beta-4 peptide. The core difference is size: the fragment isolates the actin-binding site, and the full peptide carries the rest of the sequence. Neither product is FDA-approved for human use in the United States.

What Is TB-500?

Thymosin beta-4 is a naturally occurring peptide found in nearly every mammalian cell, where it helps regulate actin, cell migration, and tissue-repair signaling. TB-500 is a synthetic research peptide modeled on that sequence and sold in lyophilized vials for laboratory work.

Naming is the biggest source of confusion. Sellers use "TB-500," "TB4," and "thymosin beta 4" almost interchangeably, even though those labels can point to slightly different molecules. The shorthand tb4 vs tb-500 exists mostly because the endogenous peptide and the synthetic research product are not always the same thing.

Preclinical animal studies have looked at TB-500 in wound healing, corneal repair, and cardiac models. Those findings are early-stage and do not establish that the peptide treats any condition in humans.

What Is TB-500 Fragment 17-23?

Fragment 17-23 is the seven-residue sequence LKKTETQ, which sits near the N-terminus of thymosin beta-4 and functions as its actin-binding domain. It appears in the scientific literature as thymosin beta 4 fragment 17-23.

Because it contains only the actin-binding region, the fragment is studied for a narrower set of questions than the full peptide. Researchers generally use it when they want to test actin sequestration or related signaling without the rest of the thymosin beta-4 sequence present.

There are practical reasons a lab might choose the shorter molecule:

• It is cheaper and faster to synthesize.
• It is easier to characterize by mass spectrometry.
• It tends to be more stable in solution than a full-length 43-mer.
• It produces cleaner results when the research question is limited to the actin-binding domain.

TB-500 Fragment 17-23 vs TB-500: Side-by-Side Comparison

Feature	TB-500 fragment 17-23	TB-500 (full-length analog)
Chain length	7 amino acids	43 amino acids
Sequence	LKKTETQ	Full thymosin beta-4 sequence
Active region	The actin-binding site itself	Contains the actin-binding site plus other domains
Typical research focus	Actin sequestration, targeted signaling	Cell migration, angiogenesis, wound and tissue-repair models
Manufacturing cost	Lower	Higher
Regulatory status in the US	Not FDA-approved for human use	Not FDA-approved for human use

The fragment is not simply a stronger version of TB-500, and TB-500 is not automatically more effective because it is longer. Each molecule answers a different experimental question.

If a study is about the actin-binding mechanism, the fragment is the more precise tool. If a study is about broader tissue-repair signaling, the full sequence is closer to what occurs naturally in cells.

Route of Administration and Research Protocols

Delivery is a separate variable from molecular size. Most animal studies use subcutaneous injection because peptides are broken down in the digestive tract and generally show poor oral bioavailability.

The online debate over tb-500 oral vs injectable usually comes down to stability and absorption rather than a real difference in the molecule. Searches for bpc-157 tb-500 oral vs injection are typically about how a peptide reaches tissue, not about which peptide is being studied.

Dosing is where self-reported protocols diverge most sharply from laboratory data. Discussions of a bpc-157 and tb-500 dosage for injury circulate widely on forums, but those numbers come from anecdote, and animal doses vary enormously between studies. No validated human dosing exists for either molecule.

Comparisons to unrelated compounds are also frequently mismatched, because a small research peptide and a recombinant hormone do not share a mechanism, a delivery route, or a regulatory pathway. Similar-sounding product names make that confusion worse.

Safety and Legal Considerations

Neither TB-500 nor its 17-23 fragment is approved by the FDA for human use. In the United States, both are sold as research chemicals and are not intended for human consumption.

Reported side effects from unsupervised use include injection-site reactions, headache, and fatigue, though formal human safety data are limited. Anyone considering a peptide for a health issue should speak with a licensed healthcare professional rather than rely on forum protocols.

Independent testing matters as well. Because the research peptide market is lightly regulated, a vial label does not guarantee the sequence inside it, and that applies equally to full-length TB-500 and to the 17-23 fragment.

Bottom Line

TB-500 fragment 17-23 is the isolated actin-binding region of thymosin beta-4, while TB-500 refers to a synthetic full-length analog. The fragment is smaller, cheaper, and more targeted; the full peptide is closer to the natural sequence and is studied in broader tissue-repair models.

Neither is FDA-approved for human use, and no controlled human trials have compared them head to head. For research purposes, the right choice depends entirely on the question being asked.

RELATED PEPTIDE TOPICTB-500 peptide

COMMON QUESTIONS

Frequently Asked Questions

Is TB-500 the same as thymosin beta 4 fragment 17-23?

Not exactly. TB-500 fragment 17-23 is a seven-amino-acid piece of thymosin beta-4, while the product labeled TB-500 is usually a synthetic version of the full 43-amino-acid peptide. Some vendors use the names loosely, so a vial label alone does not confirm which molecule you have.

Which is better, TB-500 or the 17-23 fragment?

There is no head-to-head human data, so "better" depends on the research question. The fragment is a more targeted tool for studying actin binding, while full-length TB-500 is used in broader tissue-repair models. Neither is approved for human use.

Is TB-500 legal in the United States?

TB-500 is not FDA-approved for human use and is sold as a research chemical. That means it cannot legally be marketed as a drug or dietary supplement for human consumption. Possession and import rules vary by state and can carry legal risk.